Anavex (AVXL) Life Sciences announced that it has requested the European Medicines Agency, EMA, to re-examine its opinion on blarcamesine for the treatment of early Alzheimer’s disease. Anavex has requested from the EMA the re-examination, and will work closely with the EMA during this process. The re-examination procedure is led by a different rapporteur and co-rapporteur, who will conduct a new evaluation of our marketing authorization application for blarcamesine. Anavex has also requested that the EMA consult a Scientific Advisory Group as part of this process to provide an independent recommendation.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Promising Therapeutic Potential of Blarcamesine Sparks Buy Rating for Anavex Life Sciences
- Anavex participates in a conference call with H.C. Wainwright
- Anavex announces negative CHMP opinion on blarcamesine MAA
- Anavex Life Sciences: Strategic Positioning and Potential Reversal in Alzheimer’s Treatment Boost Buy Rating
- Anavex Life Sciences: Navigating Legal Risks and Regulatory Challenges in a High-Stakes Industry